Deal between Seltek and Bio Pharm

Issue of the negotiation: Sale of Seltek’s U.S. Plant to the BioPharm

Representatives:
Seltek: Jasurbek Khabibullaev
BioPharm: KIM,EunJee

Negotiation Process;
A: Eun Jee
B: Jasurbek
B) Initial Offer: 33.7 $ Million for the Plant and Patent

A) Counter Statement: Bio Pharm has no interest in buying the patent

B) Agreement: Patent has been taken off the cost (current: 28.7 $ Million)

A) Disagreement on Insurance: 8 $ Million is not the cost rather the payment for the plant in a total loss case

thus should be omitted.

B) Counter Argument: Any asset can be insured at a certain cost, yet EunJee is right in the fact that 8 $

Million is not the cost of insurance for Seltek U.S. Plant. Thus, 4 $ Million deduction made (Current: 24.7 $

Million)

B) Final offer and Discount: Seltek agrees to deduct 700.000 $ where - 200.000 $ for tax and - 500.000 $

from the land cost since real estate market at its downturn. (Current Value 24 $ Million)

A) Statement on Public Accounting Value: Even with depreciation made for tax reducing purposes plant

value should be closer to the publicly stated value.

B) Agreement: Statement accepted and 2 $ Million deduction was made (Current Value: 22 $ Million)

Deal
BioPharm agrees on buying Seltek U.S. plant for 22 Million US dollars.
Sign Seltek: Jasurbek Khabibullaev
Sign BioPharm: Kim Eun Jee Date: 30.03.2020 (14:35)